PMC:7172841 / 969-1179 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T11","span":{"begin":87,"end":98},"obj":"Body_part"},{"id":"T12","span":{"begin":206,"end":209},"obj":"Body_part"}],"attributes":[{"id":"A11","pred":"fma_id","subj":"T11","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A12","pred":"fma_id","subj":"T12","obj":"http://purl.org/sig/ont/fma/fma84795"}],"text":"off-label Tocilizumab treatment of patients was accompanied by increase in circulating lymphocytes. Thus, the unique pattern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T15","span":{"begin":159,"end":167},"obj":"Disease"}],"attributes":[{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"off-label Tocilizumab treatment of patients was accompanied by increase in circulating lymphocytes. Thus, the unique pattern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T11","span":{"begin":4,"end":9},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"off-label Tocilizumab treatment of patients was accompanied by increase in circulating lymphocytes. Thus, the unique pattern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T8","span":{"begin":4,"end":9},"obj":"Chemical"},{"id":"T9","span":{"begin":188,"end":190},"obj":"Chemical"}],"attributes":[{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A10","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"off-label Tocilizumab treatment of patients was accompanied by increase in circulating lymphocytes. Thus, the unique pattern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T6","span":{"begin":128,"end":148},"obj":"Phenotype"}],"attributes":[{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0002958"}],"text":"off-label Tocilizumab treatment of patients was accompanied by increase in circulating lymphocytes. Thus, the unique pattern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T35","span":{"begin":10,"end":21},"obj":"DG_35"},{"id":"T36","span":{"begin":75,"end":86},"obj":"CL:0000080"},{"id":"T37","span":{"begin":87,"end":98},"obj":"CL:0000542"},{"id":"T38","span":{"begin":128,"end":134},"obj":"UBERON:0002405"},{"id":"T39","span":{"begin":135,"end":148},"obj":"GO:0065007"},{"id":"T40","span":{"begin":159,"end":167},"obj":"SP_7"},{"id":"T41","span":{"begin":188,"end":192},"obj":"PR:000001393"},{"id":"T42","span":{"begin":206,"end":209},"obj":"PR:000029150"},{"id":"T10312","span":{"begin":10,"end":21},"obj":"DG_35"},{"id":"T74668","span":{"begin":75,"end":86},"obj":"CL:0000080"},{"id":"T90672","span":{"begin":87,"end":98},"obj":"CL:0000542"},{"id":"T2958","span":{"begin":128,"end":134},"obj":"UBERON:0002405"},{"id":"T86620","span":{"begin":135,"end":148},"obj":"GO:0065007"},{"id":"T3195","span":{"begin":159,"end":167},"obj":"SP_7"},{"id":"T88472","span":{"begin":188,"end":192},"obj":"PR:000001393"},{"id":"T6458","span":{"begin":206,"end":209},"obj":"PR:000029150"}],"text":"off-label Tocilizumab treatment of patients was accompanied by increase in circulating lymphocytes. Thus, the unique pattern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-"}

{"project":"LitCovid-PubTator","denotations":[{"id":"43","span":{"begin":188,"end":192},"obj":"Gene"},{"id":"48","span":{"begin":35,"end":43},"obj":"Species"},{"id":"52","span":{"begin":10,"end":21},"obj":"Chemical"},{"id":"63","span":{"begin":159,"end":167},"obj":"Disease"}],"attributes":[{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"Gene:3569"},{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"Tax:9606"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"MESH:C502936"},{"id":"A63","pred":"tao:has_database_id","subj":"63","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"off-label Tocilizumab treatment of patients was accompanied by increase in circulating lymphocytes. Thus, the unique pattern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-"}